Large Palestinian appendectomy study reveals hidden cancers in 1.2% of specimens

A pathologist in Palestine opens a microscope slide and finds something unexpected: a tumor growing inside an appendix that was removed for what everyone thought was simple inflammation. This happens more often than anyone realized. Over twenty-two years, researchers at a multi-branch pathology laboratory examined 1,929 appendectomy specimens—the largest such series ever reported from Palestine—and discovered that hidden cancers were lurking in roughly one out of every eighty-four removed appendixes.

The study began as a straightforward accounting exercise. Between 2005 and 2026, the laboratory received 2,326 appendectomy specimens. After excluding 397 that were either mislabeled or part of larger bowel resections, the researchers had a clean cohort of 1,929 cases to analyze. The patients were mostly young—median age twenty-three—and slightly more likely to be male, with 1,125 men and 804 women in the group. What they found was a disease spectrum dominated by inflammation: three-quarters of the appendixes showed acute suppurative appendicitis, the textbook version of appendicitis that surgeons expect to find. Another 109 cases were complicated by perforation or abscess. But in 15 percent of the removals, the appendix turned out to be normal—a negative appendectomy, meaning the surgery was unnecessary. This rate climbed to 20 percent in children, suggesting that clinical diagnosis in younger patients is particularly unreliable.

The real discovery emerged when pathologists trained their attention on something else entirely. Every specimen that showed signs of neoplasia—tumor growth—was sent to a panel of specialists for careful review under the microscope, using the most current classification standards. Twenty-three specimens harbored cancers that had gone completely undetected during surgery. That is 1.2 percent of the total, a proportion that held firm across the confidence interval. The tumors were not all the same. Thirteen were low-grade appendiceal mucinous neoplasms, a slow-growing variety that produces mucus. Seven were adenocarcinomas—five of the conventional type and two mucinous variants. Three were well-differentiated neuroendocrine tumors, which arise from hormone-producing cells. None of these cancers had been suspected before the appendix was removed. None would have been caught by looking at the organ with the naked eye or during the operation itself.

Age mattered significantly in determining what disease pattern a patient would show. The statistical association between age and diagnosis category was strong and unmistakable. Sex, by contrast, made no difference—men and women carried the same distribution of disease. The rate of complicated appendicitis did not change over the twenty-two-year span, suggesting that surgical technique and patient selection remained relatively stable across the study period.

The implications are straightforward but consequential. A surgeon removes an appendix for acute inflammation and considers the job done. The specimen goes to the pathology lab, where it is typically examined to confirm what the surgeon already knows: yes, the appendix was inflamed. But that confirmation does not change how the patient is treated. The inflammation is already gone, removed from the body. What does change management is finding a cancer. A patient with an unsuspected appendiceal neoplasm needs follow-up imaging, possibly chemotherapy, possibly additional surgery. The tumor's grade and stage determine the course. This is why the researchers argue that routine histopathological examination—the careful microscopic study of every appendix—remains justified. Not because it confirms inflammation, which adds nothing to patient care, but because it catches the one tumor in eighty-four that would otherwise be missed, a neoplasm that carries real consequences for how the patient's illness unfolds.